Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected Healthcare Workers

被引:2
|
作者
Algarate, Sonia [1 ,2 ,3 ]
Serrano, Laura [1 ,3 ]
Bueno, Jessica [1 ,2 ]
Herrero-Cortina, Beatriz [1 ,3 ,4 ]
Alvarado, Elena [1 ]
Gonzalez-Barriga, Maria T. [1 ,3 ]
Ducons, Maria [1 ]
Montero-Marco, Jesica [1 ,3 ]
Arnal, Sara [1 ]
Acha, Beatriz [1 ,3 ]
Riesgo, Maria [1 ]
Taboada, Ana [1 ,3 ]
Sanz-Burillo, Pilar [1 ,3 ]
Yuste, Cristina [1 ,3 ]
Benito, Rafael [1 ,2 ,3 ]
机构
[1] Hosp Clin Univ Lozano Blesa Zaragoza, Ave San Juan Bosco 15, Zaragoza 50009, Spain
[2] Univ Zaragoza, Microbiol Dept, Calle Pedro Cerbuna 12, Zaragoza 50009, Spain
[3] Inst Invest Sanitaria Aragon, Ave San Juan Bosco 13, Zaragoza 50009, Spain
[4] Univ San Jorge, Nursing Dept, Autovia Mudejar,Km 299, Zaragoza 50830, Spain
关键词
SARS-CoV-2; booster vaccine; post-vaccine IgG antibody persistence;
D O I
10.3390/ijms241310713
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months after the second dose, 389 voluntary, immunocompetent, non-pregnant healthcare workers received a booster dose of SARS-CoV-2 vaccine, and a serum sample was obtained. Two groups of patients were established: with and without previous SARS-CoV-2 infection. In order to quantify anti-S1 IgG (AU/mL) we used CMIA (Abbott). All of the health workers were anti-S IgG positive 8 months after receiving the booster dose of the vaccine, with a mean of 17,040 AU/mL. In 53 patients without previous infection, antibody levels increased by a mean of 10,762 AU/mL. This figure is seven times higher than the one produced after the second dose (1506 AU/mL). The booster dose produces a robust elevation of the antibody level, which persists at 8 months, with levels significantly higher than those reached after the second dose, which allow one to predict a persistence of more than one year. The study demonstrates the efficacy of the booster dose of anti-SARS-CoV-2 vaccines.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria
    Chalupka, Alena
    Richter, Lukas
    Chakeri, Ali
    El-Khatib, Ziad
    Theiler-Schwetz, Verena
    Trummer, Christian
    Krause, Robert
    Willeit, Peter
    Benka, Bernhard
    Ioannidis, John P. A.
    Pilz, Stefan
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (03)
  • [22] Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine
    Marc, Gonzalo Perez
    Alvarez-Paggi, Damian
    Polack, Fernando P.
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (12):
  • [23] Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection
    Elslande, Jan Van
    Oyaert, Matthijs
    Ailliet, Scott
    Ranst, Marc Van
    Lorent, Natalie
    Weygaerde, Yannick Vande
    Andre, Emmanuel
    Lagrou, Katrien
    Vandendriessche, Stien
    Vermeersch, Pieter
    JOURNAL OF CLINICAL VIROLOGY, 2021, 136
  • [24] Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster
    Salvagno, G. L.
    Henry, B. M.
    Lippi, G.
    INFECTIOUS DISEASES NOW, 2022, 52 (06): : 379 - 380
  • [25] Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
    Quiroga, Borja
    Jose Soler, Maria
    Ortiz, Alberto
    Jaravaca Mantecon, Carlos Jesus
    Nava Perez, Nathasha
    Serra Martin, Marta
    Sato, Yurika
    Marin Franco, Antonio Jose
    Pazmino Zambrano, Diana Flor
    Lucena Valverde, Rafael
    Ortega Diaz, Mayra
    Calderon Gonzalez, Carmen
    Cazorla Lopez, Juan Manuel
    Pereira, Monica
    Gonzalez Parra, Emilio
    Sanchez Horrillo, Ana
    Sanchez Gonzalez, Carmen
    Toapanta, Nestor
    Cigarran Guldris, Secundino
    Sanchez Hernandez, Rosa
    Pizarro Sanchez, Soledad
    Muniz Rincon, Maria
    Garcia-Fernandez, Nuria
    Blanco Castro, Natalia
    Collantes Mateo, Rocio
    Quiroz Morales, Manuel Augusto
    Escamilla-Cabrera, Beatriz
    Berdud Godoy, Isabel
    Gil-Casares Casanova, Beatriz
    Leyva, Alba
    Rojas, Jose
    Gansevoort, Ron T.
    de Sequera, Patricia
    CLINICAL KIDNEY JOURNAL, 2022, 15 (10) : 1856 - 1864
  • [26] Role of anti-Spike SARS-CoV-2 IgG antibodies in protection from SARS-CoV-2 Infection after booster vaccination
    Senn, A.
    Brueckner-Fracowiak, J.
    Kostyra, J.
    Biedermann, S.
    Fux, A.
    Bach, A.
    Schuster, M.
    Baurmann, H.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 : 363 - 363
  • [27] Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?
    Achiron, Anat
    Mandel, Mathilda
    Dreyer-Alster, Sapir
    Harari, Gil
    Gurevich, Michael
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2021, 94 : 105 - 107
  • [28] SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers
    Nunes, Marta C.
    Mbotwe-Sibanda, Sthembile
    Baillie, Vicky L.
    Kwatra, Gaurav
    Aguas, Ricardo
    Madhi, Shabir A.
    VACCINES, 2022, 10 (03)
  • [29] Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination
    Zember, Sanja
    Bodulic, Kristian
    Balent, Natasa Cetinic
    Mikulic, Radojka
    Markotic, Alemka
    Rode, Oktavija Dakovic
    VACCINES, 2022, 10 (11)
  • [30] SARS-CoV-2 IgG response in symptomatic and asymptomatic COVID-19-infected healthcare workers
    Cordova, E.
    Bacelar, B.
    Nieto, F.
    Garibaldi, F.
    Aguirre, V
    Machuca, M.
    Badia, M.
    Rodriguez, C.
    OCCUPATIONAL MEDICINE-OXFORD, 2021, 71 (4-5): : 215 - 218